Drug-Diagnostic Co-Development in Cancer
@article{Winther2012DrugDiagnosticCI, title={Drug-Diagnostic Co-Development in Cancer}, author={Henrik Winther and J. J{\o}rgensen}, journal={Pharmaceutical Medicine}, year={2012}, volume={24}, pages={363-375} }
Within oncology, companion diagnostics are considered to be of important value as the efficacy rates of anticancer pharmacotherapy in many cases remain low. Both the costs and the consequences of treatment failure are significant. Drug-diagnostic combinations have been known for several decades within oncology and the preselection of patients based on the differences in their biology was practiced as early as the 1970s. In relation to the development of the first companion diagnostic (for the… CONTINUE READING
Figures, Tables, and Topics from this paper
14 Citations
Companion Diagnostics for Targeted Cancer Drugs – Clinical and Regulatory Aspects
- Medicine
- Front. Oncol.
- 2014
- 66
- PDF
Targeted drugs and diagnostic assays: Companions in the race to combat ethnic disparity.
- Medicine
- Frontiers in bioscience
- 2017
- 3
- PDF
The HER2 CISH pharmDx™ Kit in the assessment of breast cancer patients for anti-HER2 treatment
- Biology, Medicine
- Expert review of molecular diagnostics
- 2013
- 5
A challenging drug development process in the era of personalized medicine.
- Medicine
- Drug discovery today
- 2011
- 44
Paving the road to personalized medicine: recommendations on regulatory, intellectual property and reimbursement challenges
- Medicine
- Journal of law and the biosciences
- 2017
- 12
- PDF
In Vitro Effect of Pomalidomide on Bone Marrow Mononuclear Cells From Multiple Myeloma Patients
- Medicine
- 2018
- PDF
References
SHOWING 1-10 OF 50 REFERENCES
Pharmacodiagnostics and targeted therapies - a rational approach for individualizing medical anticancer therapy in breast cancer.
- Medicine
- The oncologist
- 2007
- 43
- PDF
Opportunities and challenges in the development of targeted therapies.
- Medicine
- Seminars in oncology
- 2004
- 31
The role of companion diagnostics in the development and use of mutation-targeted cancer therapies
- Medicine
- Nature Biotechnology
- 2006
- 124
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
- Medicine
- The New England journal of medicine
- 2008
- 3,137
- PDF
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
- Medicine
- The New England journal of medicine
- 2001
- 9,074
- Highly Influential
- PDF
Treatment options in metastatic renal carcinoma: an embarrassment of riches.
- Medicine
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology
- 2006
- 125
Randomized Phase III Clinical Trial Designs for Targeted Agents
- Medicine
- Clinical Cancer Research
- 2008
- 87
- PDF